KRAS and colorectal carcinoma: These drugs have proved to be ineffective against CRC [6]; however, there may still be hope since FGTI-2734, a recently developed peptide inhibitor, can disrupt KRAS membrane localisation in various human cancer cell lines, including the DLD1 colon cancer cell line [9].